Corium International (NASDAQ:CORI) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other analysts have also weighed in on the stock. HC Wainwright set a $15.00 price objective on shares of Corium International and gave the stock a “buy” rating in a research note on Friday, November 17th. ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a research note on Friday, December 22nd. Zacks Investment Research upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, November 28th. Finally, Needham & Company LLC cut their price objective on shares of Corium International from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, December 26th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.86.

How to Become a New Pot Stock Millionaire

Corium International (NASDAQ:CORI) opened at $11.92 on Tuesday. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40. Corium International has a 52 week low of $3.50 and a 52 week high of $13.93. The stock has a market cap of $430.60, a P/E ratio of -7.59 and a beta of 1.50.

Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The business had revenue of $9.32 million for the quarter, compared to analyst estimates of $7.48 million. equities research analysts expect that Corium International will post -1.43 earnings per share for the current fiscal year.

In other news, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were bought at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were purchased at an average price of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in Corium International by 14.0% during the fourth quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 11,900 shares during the period. Geode Capital Management LLC grew its position in Corium International by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock valued at $2,147,000 after buying an additional 12,745 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Corium International during the fourth quarter valued at $123,000. Schwab Charles Investment Management Inc. grew its position in Corium International by 47.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 15,909 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Corium International by 126.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 18,416 shares during the period. Institutional investors own 88.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Corium International (CORI) to Hold” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/03/14/bidaskclub-lowers-corium-international-cori-to-hold.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.